Bayer Poised to Navigate Patent Cliff with Blockbuster Hopefuls for Stroke, Kidney Disease

Christoph Koenen (right), Global Head of Clinical Development and Operations, and Max Wegner, Head of Regulatory Affairs, at Bayer’s Tokyo Office on April 23 As patent expirations loom large for its big-name brands like Eylea (aflibercept), Bayer hopes to groom...read more